60 Degrees Pharmaceuticals, Inc. (SXTP) Fair Value 2026

SXTP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (17/100)

Quick Summary — As of 2026-08-28, 60 Degrees Pharmaceuticals, Inc. (SXTP) trades at $1.03. QOC: 5.7/10. Value Trap Risk: 17/100 (SAFE). 1/13 models active.

Key Facts

Ticker
SXTP
Price
$1.03
Quality Score
5.7/10
Value Trap Risk
17/100
Models Active
1/13
Last Updated
Strength: ML-RIV suggests +81.2% upside with 53% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give SXTP?

1 Intrinsic Value Models vs. Current Price ($1.03)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.87 +81.2%

All Models Active

All 1 models are displayed above.

What Is 60 Degrees Pharmaceuticals, Inc. (SXTP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, 60 Degrees Pharmaceuticals, Inc. is potentially undervalued at its current price of $1.03. Based on our 13-model framework, 60 Degrees Pharmaceuticals, Inc.'s intrinsic value is estimated at a median fair value of $1.87 — representing +81.2% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About SXTP?

1 of 13 models are currently active for SXTP. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does SXTP Rank in Biotechnology?

Among 625 Biotechnology stocks, SXTP ranks #182 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, 60 Degrees Pharmaceuticals, Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is SXTP a Value Trap?

CirclFi's Value Trap algorithm assigns SXTP a score of 17/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for 60 Degrees Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, 60 Degrees Pharmaceuticals, Inc. is rated at 5.7/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SXTP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SXTP's 1 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy 60 Degrees Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

GOVXGeoVax Labs, Inc.QOC 5.7TRDAEntrada Therapeutics, Inc.QOC 5.7OABIOmniAb, Inc.QOC 5.7NRXSNeurAxis, Inc.QOC 5.7ATAIAtaiBeckley Inc.QOC 5.8MGXMetagenomi Therapeutics, Inc.QOC 5.7CGEMCullinan Therapeutics, Inc.QOC 4.9CLDICalidi Biotherapeutics, Inc.QOC 4.3TBPHTheravance Biopharma, Inc.QOC 8.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: GOVX · TRDA · OABI · NRXS · ATAI · MGX · CGEM · CLDI · TBPH · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SXTP?

7 companies across all industries closest to SXTP’s Quality of Company score of 5.7/10.

CENNCenntro Inc.QOC 5.7SBSWSibanye Stillwater LimitedQOC 5.7CRWVCoreWeave, Inc.QOC 5.7CIITTianci International, Inc.QOC 5.7VNRXVolitionRx LimitedQOC 5.7LQMTLiquidmetal Technologies, Inc.QOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CENN · SBSW · CRWV · CIIT · VNRX · LQMT · NVDA

Where Does SXTP Sit in CirclFi's Biotechnology Rankings?

SXTP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About 60 Degrees Pharmaceuticals, Inc.’s Valuation?

What is 60 Degrees Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for 60 Degrees Pharmaceuticals, Inc. (SXTP). The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SXTP overvalued or undervalued right now?

At $1.03, 1 of 1 active models suggest SXTP may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits 60 Degrees Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.7 mean for SXTP?

60 Degrees Pharmaceuticals, Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SXTP?

CirclFi analyzes SXTP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SXTP a value trap in 2026?

60 Degrees Pharmaceuticals, Inc.'s Value Trap score is 17/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns 60 Degrees Pharmaceuticals, Inc. (SXTP) a Quality of Company score of 5.7/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SXTP/ · Methodology
Primary sources for this SXTP valuation
  • Financial statements: 60 Degrees Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001946563) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SXTP as of ; valuations recomputed .